MYC sensitises cells to apoptosis by driving energetic demand.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
09 08 2022
Historique:
received: 16 02 2022
accepted: 27 07 2022
entrez: 9 8 2022
pubmed: 10 8 2022
medline: 12 8 2022
Statut: epublish

Résumé

The MYC oncogene is a potent driver of growth and proliferation but also sensitises cells to apoptosis, which limits its oncogenic potential. MYC induces several biosynthetic programmes and primary cells overexpressing MYC are highly sensitive to glutamine withdrawal suggesting that MYC-induced sensitisation to apoptosis may be due to imbalance of metabolic/energetic supply and demand. Here we show that MYC elevates global transcription and translation, even in the absence of glutamine, revealing metabolic demand without corresponding supply. Glutamine withdrawal from MRC-5 fibroblasts depletes key tricarboxylic acid (TCA) cycle metabolites and, in combination with MYC activation, leads to AMP accumulation and nucleotide catabolism indicative of energetic stress. Further analyses reveal that glutamine supports viability through TCA cycle energetics rather than asparagine biosynthesis and that TCA cycle inhibition confers tumour suppression on MYC-driven lymphoma in vivo. In summary, glutamine supports the viability of MYC-overexpressing cells through an energetic rather than a biosynthetic mechanism.

Identifiants

pubmed: 35945217
doi: 10.1038/s41467-022-32368-z
pii: 10.1038/s41467-022-32368-z
pmc: PMC9363429
doi:

Substances chimiques

Proto-Oncogene Proteins c-myc 0
Glutamine 0RH81L854J

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

4674

Subventions

Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/P010008/2
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C49940/A17480
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C355/A25137
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_PC_17230
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C47559/A16243
Pays : United Kingdom

Informations de copyright

© 2022. The Author(s).

Références

J Cell Biol. 2007 Jul 2;178(1):93-105
pubmed: 17606868
Cell Rep. 2016 Oct 11;17(3):876-890
pubmed: 27732861
Mol Cell. 2014 Oct 23;56(2):205-218
pubmed: 25242145
Science. 1994 Sep 30;265(5181):2091-3
pubmed: 8091232
Proc Natl Acad Sci U S A. 2008 Dec 2;105(48):18782-7
pubmed: 19033189
Cell. 2011 Apr 29;145(3):435-46
pubmed: 21529715
J Mol Med (Berl). 2011 Nov;89(11):1137-48
pubmed: 21769686
Biochem Soc Trans. 2011 Jan;39(1):1-13
pubmed: 21265739
Anal Chem. 2017 Sep 19;89(18):9616-9619
pubmed: 28850215
Cell. 1992 Apr 3;69(1):119-28
pubmed: 1555236
Cell. 2012 Sep 28;151(1):68-79
pubmed: 23021216
Cell. 1997 Nov 28;91(5):627-37
pubmed: 9393856
Nature. 2003 Jan 16;421(6920):290-4
pubmed: 12529648
Mol Cell Biol. 2000 Aug;20(15):5680-9
pubmed: 10891504
Nature. 2014 Nov 20;515(7527):431-435
pubmed: 25383517
Oncogene. 1998 Jul 23;17(3):339-46
pubmed: 9690515
Cancer Metab. 2014 Mar 10;2(1):4
pubmed: 24612826
Nature. 1992 Oct 8;359(6395):554-6
pubmed: 1406976
Nat Immunol. 2016 Jun;17(6):712-20
pubmed: 27111141
Am J Physiol. 1993 May;264(5 Pt 1):C1246-51
pubmed: 8498484
Cell Cycle. 2008 Aug;7(15):2392-400
pubmed: 18677108
Nature. 2014 Jul 24;511(7510):488-492
pubmed: 25043028
Nat Metab. 2020 Apr;2(4):335-350
pubmed: 32694609
Anal Chem. 2014 Feb 4;86(3):1632-9
pubmed: 24397582
Mol Cell. 1998 Feb;1(3):327-36
pubmed: 9660917
Cancer Cell. 2015 Feb 9;27(2):271-85
pubmed: 25640402
Nat Biotechnol. 2008 Dec;26(12):1367-72
pubmed: 19029910
PLoS Genet. 2016 Feb 18;12(2):e1005867
pubmed: 26889675
EMBO J. 1994 Nov 15;13(22):5442-50
pubmed: 7957110
Nat Cell Biol. 2005 Mar;7(3):295-302
pubmed: 15723055
Oncogene. 2009 Jul 9;28(27):2485-91
pubmed: 19448666
Cancer Cell. 2006 Aug;10(2):113-20
pubmed: 16904610
Cell. 1993 Oct 22;75(2):241-51
pubmed: 7503812
Cell Metab. 2012 Jan 4;15(1):110-21
pubmed: 22225880
Cell. 2012 Sep 28;151(1):56-67
pubmed: 23021215
Oncogene. 2013 Apr 4;32(14):1821-30
pubmed: 22614006
Semin Cancer Biol. 1993 Feb;4(1):3-12
pubmed: 8448376
Clin Chim Acta. 1981;115(1):73-84
pubmed: 7261408
Trends Cancer. 2021 Aug;7(8):790-804
pubmed: 34020912
Nature. 2014 Jul 24;511(7510):483-7
pubmed: 25043018
Cancer Res. 2005 Dec 15;65(24):11565-71
pubmed: 16357166
Cell. 2014 May 22;157(5):1088-103
pubmed: 24855946
J Biol Chem. 2001 Jun 1;276(22):19414-9
pubmed: 11259441
Proc Natl Acad Sci U S A. 1999 Nov 9;96(23):13180-5
pubmed: 10557294
Nat Cell Biol. 2005 Mar;7(3):303-10
pubmed: 15723053
Proc Natl Acad Sci U S A. 2002 Oct 1;99(20):12801-6
pubmed: 12228733
Nature. 2013 Feb 14;494(7436):251-5
pubmed: 23302800
Biochem J. 2006 Apr 1;395(1):57-64
pubmed: 16321138
Annu Rev Physiol. 1985;47:727-49
pubmed: 2581508
J Biol Chem. 2004 Feb 6;279(6):4305-12
pubmed: 14627695
PLoS One. 2008 Jul 16;3(7):e2722
pubmed: 18628958
J Biol Chem. 2006 Apr 21;281(16):10890-5
pubmed: 16464852
Mol Cell. 1999 Feb;3(2):159-67
pubmed: 10078199
Oncotarget. 2015 May 20;6(14):12587-602
pubmed: 25869206
Nat Cell Biol. 2005 Mar;7(3):311-8
pubmed: 15723054
Genes Dev. 2003 May 1;17(9):1115-29
pubmed: 12695333
Immunity. 2011 Dec 23;35(6):871-82
pubmed: 22195744
Mol Cell Biol. 2001 Nov;21(22):7653-62
pubmed: 11604501

Auteurs

Joy Edwards-Hicks (J)

Cancer Research UK Edinburgh Centre, Institute of Genetics and Cancer, University of Edinburgh, Crewe Road South, Edinburgh, EH4 2XR, UK.
Department of Immunometabolism, Max Planck Institute of Immunobiology and Epigenetics, Stübeweg 51, D-79108, Freiburg, Germany.

Huizhong Su (H)

Cancer Research UK Edinburgh Centre, Institute of Genetics and Cancer, University of Edinburgh, Crewe Road South, Edinburgh, EH4 2XR, UK.

Maurizio Mangolini (M)

Wellcome Trust/MRC Cambridge Stem Cell Institute & Department of Haematology, University of Cambridge, Cambridge, CB2 0AH, UK.

Kubra K Yoneten (KK)

Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London, EC1M 6BQ, UK.

Jimi Wills (J)

Cancer Research UK Edinburgh Centre, Institute of Genetics and Cancer, University of Edinburgh, Crewe Road South, Edinburgh, EH4 2XR, UK.

Giovanny Rodriguez-Blanco (G)

Cancer Research UK Edinburgh Centre, Institute of Genetics and Cancer, University of Edinburgh, Crewe Road South, Edinburgh, EH4 2XR, UK.

Christine Young (C)

MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Crewe Road South, Edinburgh, EH4 2XR, UK.

Kevin Cho (K)

Department of Chemistry and Medicine, Washington University School of Medicine, St. Louis, MO, 63110, USA.

Heather Barker (H)

Cancer Research UK Edinburgh Centre, Institute of Genetics and Cancer, University of Edinburgh, Crewe Road South, Edinburgh, EH4 2XR, UK.

Morwenna Muir (M)

Cancer Research UK Edinburgh Centre, Institute of Genetics and Cancer, University of Edinburgh, Crewe Road South, Edinburgh, EH4 2XR, UK.

Ania Naila Guerrieri (AN)

Cancer Research UK Edinburgh Centre, Institute of Genetics and Cancer, University of Edinburgh, Crewe Road South, Edinburgh, EH4 2XR, UK.

Xue-Feng Li (XF)

MRC University of Edinburgh Centre for Reproductive Health, University of Edinburgh, Edinburgh, EH16 4TJ, UK.

Rachel White (R)

Cancer Research UK Edinburgh Centre, Institute of Genetics and Cancer, University of Edinburgh, Crewe Road South, Edinburgh, EH4 2XR, UK.

Piotr Manasterski (P)

Cancer Research UK Edinburgh Centre, Institute of Genetics and Cancer, University of Edinburgh, Crewe Road South, Edinburgh, EH4 2XR, UK.

Elena Mandrou (E)

Cancer Research UK Edinburgh Centre, Institute of Genetics and Cancer, University of Edinburgh, Crewe Road South, Edinburgh, EH4 2XR, UK.

Karen Wills (K)

Cancer Research UK Edinburgh Centre, Institute of Genetics and Cancer, University of Edinburgh, Crewe Road South, Edinburgh, EH4 2XR, UK.

Jingyu Chen (J)

Wellcome Trust/MRC Cambridge Stem Cell Institute & Department of Haematology, University of Cambridge, Cambridge, CB2 0AH, UK.

Emily Abraham (E)

Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London, EC1M 6BQ, UK.

Kianoosh Sateri (K)

Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London, EC1M 6BQ, UK.

Bin-Zhi Qian (BZ)

Cancer Research UK Edinburgh Centre, Institute of Genetics and Cancer, University of Edinburgh, Crewe Road South, Edinburgh, EH4 2XR, UK.
MRC University of Edinburgh Centre for Reproductive Health, University of Edinburgh, Edinburgh, EH16 4TJ, UK.

Peter Bankhead (P)

Centre for Genomic and Experimental Medicine, Institute of Genetics and Molecular Medicine, University of Edinburgh, Crewe Road South, Edinburgh, EH4 2XR, UK.

Mark Arends (M)

Cancer Research UK Edinburgh Centre, Institute of Genetics and Cancer, University of Edinburgh, Crewe Road South, Edinburgh, EH4 2XR, UK.

Noor Gammoh (N)

Cancer Research UK Edinburgh Centre, Institute of Genetics and Cancer, University of Edinburgh, Crewe Road South, Edinburgh, EH4 2XR, UK.

Alex von Kriegsheim (A)

Cancer Research UK Edinburgh Centre, Institute of Genetics and Cancer, University of Edinburgh, Crewe Road South, Edinburgh, EH4 2XR, UK.

Gary J Patti (GJ)

Department of Chemistry and Medicine, Washington University School of Medicine, St. Louis, MO, 63110, USA.

Andrew H Sims (AH)

Cancer Research UK Edinburgh Centre, Institute of Genetics and Cancer, University of Edinburgh, Crewe Road South, Edinburgh, EH4 2XR, UK.

Juan Carlos Acosta (JC)

Cancer Research UK Edinburgh Centre, Institute of Genetics and Cancer, University of Edinburgh, Crewe Road South, Edinburgh, EH4 2XR, UK.
Instituto de Biomedicina y Biotecnología de Cantabria, IBBTEC (CSIC, Universidad de Cantabria). C/ Albert Einstein 22, Santander, 39011, Spain.

Valerie Brunton (V)

Cancer Research UK Edinburgh Centre, Institute of Genetics and Cancer, University of Edinburgh, Crewe Road South, Edinburgh, EH4 2XR, UK.

Kamil R Kranc (KR)

Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London, EC1M 6BQ, UK.
MRC Center for Regenerative Medicine, University of Edinburgh, Edinburgh, EH8 9YL, UK.

Maria Christophorou (M)

Wellcome Trust/MRC Cambridge Stem Cell Institute & Department of Haematology, University of Cambridge, Cambridge, CB2 0AH, UK.

Erika L Pearce (EL)

Department of Immunometabolism, Max Planck Institute of Immunobiology and Epigenetics, Stübeweg 51, D-79108, Freiburg, Germany.
Department of Oncology, The Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University, Baltimore, MD, USA.

Ingo Ringshausen (I)

Wellcome Trust/MRC Cambridge Stem Cell Institute & Department of Haematology, University of Cambridge, Cambridge, CB2 0AH, UK.

Andrew J Finch (AJ)

Cancer Research UK Edinburgh Centre, Institute of Genetics and Cancer, University of Edinburgh, Crewe Road South, Edinburgh, EH4 2XR, UK. a.finch@qmul.ac.uk.
Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London, EC1M 6BQ, UK. a.finch@qmul.ac.uk.

Articles similaires

T-Lymphocytes, Regulatory Lung Neoplasms Proto-Oncogene Proteins p21(ras) Animals Humans

Pathogenic mitochondrial DNA mutations inhibit melanoma metastasis.

Spencer D Shelton, Sara House, Luiza Martins Nascentes Melo et al.
1.00
DNA, Mitochondrial Humans Melanoma Mutation Neoplasm Metastasis
Killer Cells, Natural Animals Colorectal Neoplasms Decorin Adenoviridae
Animals Humans Nickel Mice Immunotherapy

Classifications MeSH